EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preclinical Evaluation of Combined Polo-like Kinase 1 Inhibition and Navitoclax in Experimental Models of Lung Cancer

Bárbara Pinto, Mateus Prates-Rodrigues iD, Daniel Augusto Barnabe Nobre iD, Mariana de Oliveira Silva iD, Bárbara M de Amorim-Santos iD, João P N Silva iD, Patrícia M A Silva iD, Bruno Sarmento, Marisa Salvi iD, Geovanni Dantas Cassali iD, Elaine Maria de Souza-Fagundes, Hassan Bousbaa iD und 1 weitere

International Journal of Molecular Sciences · 17.08.2026 · 27 (16) · 7359

DOI: 10.3390/ijms27167359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.08.2026. Verfasst von Bárbara Pinto und 12 weiteren Autor:innen. Beteiligte Einrichtung: UNIPRO-Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Politécnico e …. Hauptthemen laut MEDLINE: Aniline Compounds, Sulfonamides, Protein Serine-Threonine Kinases, Cell Cycle Proteins. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Minas Gerais Network for Translational Research in Immunobiologicals and Biopharmaceuticals in Cancer, CESPU-Cooperativa de Ensino Superior Politécnico e Universitário Crl, Fundação para a Ciência e a Tecnologia (FCT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted therapies have substantially advanced cancer treatment; however, therapeutic resistance remains a major challenge, particularly in lung cancer. Polo-like kinase 1 (PLK-1), a key regulator of mitosis, is frequently overexpressed in lung tumors and has emerged as an attractive anticancer target. Although PLK-1 inhibition induces robust antitumor effects in preclinical models, its translation into clinical benefit has been limited, particularly when used as monotherapy. Previous in vitro work from our group demonstrated that combining PLK-1 inhibition with the pro-apoptotic agent Navitoclax markedly enhanced cancer cell death by reducing mitotic slippage and promoting post-mitotic apoptosis. Here, we investigated whether this combinatorial strategy translates into therapeutic benefit in vivo. Using Lewis lung carcinoma (LLC1) cells, we evaluated the effects of BI2536 (a PLK-1 inhibitor) and Navitoclax, alone or in combination, in vitro and in male C57BL/6J mice using three lung cancer models: subcutaneous, intranasal, and intrapulmonary. The in vitro results corroborated the findings of our previous work, demonstrating synergistic effects. In the murine models, tumor progression, body weight, survival, and histopathological features were assessed to evaluate therapeutic efficacy and systemic toxicity. In the subcutaneous model, BI2536 monotherapy significantly reduced tumor volume compared with vehicle-treated controls, while Navitoclax alone and the combination therapy also produced tumor growth inhibition. In contrast, in the intranasal model, no significant differences were observed in body weight or survival among groups. Nonetheless, treatment with BI2536 alone or in combination with Navitoclax significantly reduced tumor cell proliferative activity. In the aggressive intrapulmonary (orthotopic) model, rapid disease progression and high mortality were observed across all groups. Notably, BI2536 treatment was associated with improved survival compared with Navitoclax monotherapy, whereas the combination therapy did not confer additional survival benefit. Histological analyses revealed highly proliferative tumors with pronounced cellular and nuclear atypia. Moreover, the BI2536 monotherapy group exhibited significantly greater necrosis/apoptosis than the other treatment groups, while diffuse and focal hepatic steatosis was observed exclusively in the combination group. Together, these findings indicate that while PLK-1 inhibition exerts antitumor effects in certain in vivo contexts, the therapeutic synergy observed in vitro with Navitoclax does not consistently translate to in vivo lung cancer models. This study highlights the challenges of translating combinatorial mitotic and apoptotic targeting strategies into effective in vivo therapies and underscores the importance of model selection and tumor microenvironment in preclinical drug evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aniline CompoundsSulfonamidesProtein Serine-Threonine KinasesCell Cycle ProteinsProto-Oncogene ProteinsLung NeoplasmsPteridinesProtein Kinase InhibitorsCarcinoma, Lewis LungAntineoplastic AgentsAnimalsMicePolo-Like Kinase 1MaleMice, Inbred C57BLCell Line, TumorApoptosisDisease Models, AnimalHumansDrug SynergismCell Proliferation

Stichwörter der Autor:innen

BI2536NavitoclaxPLK-1combination therapylung cancer animal models

Substanzen

Aniline CompoundsSulfonamidesProtein Serine-Threonine KinasesnavitoclaxCell Cycle ProteinsProto-Oncogene ProteinsPolo-Like Kinase 1PteridinesBI 2536Protein Kinase Inhibitors

Autor:innen und Institutionen

  • UNIPRO-Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), 4585-116 Gandra, Portugal.
  • Department of Physiology and Biophysics, Institute of Biological Sciences, Federal University of Minas Gerais (UFMG), Av. Pres. Antônio Carlos, 6627, Belo Horizonte 31270-901, Brazil.
  • UCIBIO-Applied Molecular Biosciences Unit, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal.
  • Department of Microbiology, Institute of Biological Sciences, Federal University of Minas Gerais (UFMG), Av. Pres. Antônio Carlos, 6627, Belo Horizonte 31270-901, Brazil.
  • Associate Laboratory i4HB-Institute for Health and Bioeconomy, University Institute of Health Sciences-CESPU, 4585-116 Gandra, Portugal.
  • i3S-Institute for Research and Innovation in Health, University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal.

ORCID-Profile: Mateus Prates-Rodrigues, Daniel Augusto Barnabe Nobre, Mariana de Oliveira Silva, Bárbara M de Amorim-Santos, João P N Silva, Patrícia M A Silva, Marisa Salvi, Geovanni Dantas Cassali, Hassan Bousbaa

Förderung

  • Minas Gerais Network for Translational Research in Immunobiologicals and Biopharmaceuticals in Cancer
  • CESPU-Cooperativa de Ensino Superior Politécnico e Universitário Crl
  • Fundação para a Ciência e a Tecnologia (FCT)
  • Fundação de Amparo à Pesquisa do Estado de Minas Gerais
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
  • National Council for Scientific and Technological Development (CNPq)
  • CESPU—Cooperativa de Ensino Superior Politécnico e Universitário Crl

Zitieren

APA

Pinto, B., Prates-Rodrigues, M., Nobre, D. A. B., Silva, M. O., de Amorim-Santos, B. M., Silva, J. P. N., Silva, P. M. A., Sarmento, B., Salvi, M., Cassali, G. D., Souza-Fagundes, E. M., Bousbaa, H., & Carvalho-Tavares, J. (2026). Preclinical Evaluation of Combined Polo-like Kinase 1 Inhibition and Navitoclax in Experimental Models of Lung Cancer. International Journal of Molecular Sciences, 27(16), 7359. https://doi.org/10.3390/ijms27167359

Vancouver

Pinto B, Prates-Rodrigues M, Nobre DAB, Silva MO, de Amorim-Santos BM, Silva JPN, et al. Preclinical Evaluation of Combined Polo-like Kinase 1 Inhibition and Navitoclax in Experimental Models of Lung Cancer. International Journal of Molecular Sciences. 2026;27(16):7359. doi:10.3390/ijms27167359

BibTeX
@article{Pinto2026,
  author = {Pinto, Bárbara and Prates-Rodrigues, Mateus and Nobre, Daniel Augusto Barnabe and Silva, Mariana de Oliveira and de Amorim-Santos, Bárbara M and Silva, João P N and Silva, Patrícia M A and Sarmento, Bruno and Salvi, Marisa and Cassali, Geovanni Dantas and Souza-Fagundes, Elaine Maria de and Bousbaa, Hassan and Carvalho-Tavares, Juliana},
  title = {Preclinical Evaluation of Combined Polo-like Kinase 1 Inhibition and Navitoclax in Experimental Models of Lung Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {16},
  pages = {7359},
  doi = {10.3390/ijms27167359}
}
Kostenlos starten →